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The treatment of essential hypertension is based essentially on the prescription of four major classes of antihypertensive drugs, i.e. blockers of the
renin–angiotensin system, calcium channel blockers, diuretics and beta-blockers. In recent years, very few new drug therapies of hypertension
have become available. Therefore, it is crucial for physicians to optimize their antihypertensive therapies with the drugs available on the market. In
eachof the classesof antihypertensivedrugs, questionshave recentlybeen raised: areangiotensin-convertingenzyme (ACE) inhibitors superior to
angiotensin II receptor blockers (ARB)? Is it possible to reduce the incidence of peripheral oedema with calcium antagonists? Is hydrochlorothia-
zide really thegooddiuretic touse in combination therapies?Thepurposeof this review is todiscuss thesevariousquestions in the lightof themost
recent clinical studies and meta-analyses. These latter suggest that ACE inhibitors and ARB are equivalent except for a better tolerability profile of
ARB. Third generation calcium channel blockers enable to reduce the incidence of peripheral oedema and chlorthalidone is certainly more
effective than hydrochlorothiazide in preventing cardiovascular events in hypertension. At last, studies suggest that drug adherence and
long-term persistence under therapy is one of the major issues in the actual management of essential hypertension.
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Introduction
The management of patients with essential hypertension is based es-
sentially on the prescription of antihypertensive drugs that enable to
lower blood pressure to the recommended targets of ,140/
90 mmHg in the general population and to lower levels (,135/
85 mmHg) for some patient groups such as diabetics or patients
with chronic kidney diseases.1,2 During the last 10 years, very few
new antihypertensive agents have reached the market and no new
therapeutic class has really emerged if one considers renin inhibitors
as members of drugs inhibiting the renin–angiotensin system (RAS).
Thus, the actual strategy to control blood pressure in hypertension
relies on the use of three major classes of antihypertensive drugs, i.e.
blockers of the RAS, calcium channel blockers (CCBs), and diuretics
(D) as reported in the last 2013 hypertension guidelines of the Euro-
pean Society of Hypertension and European Society of Cardiology.3
In some clinical conditions such as patients with coronary heart
disease and heart failure, beta-blockers still have their place and this
is the reason why they have been maintained in the 2013 hypertension
guidelines.3 Drugs, such as peripheral vasodilators, nitrates, or
alpha-adrenergic blockers, are no longer recommended as first-line
therapies although they might be useful in rare circumstances such
as hypertensive blacks with heart failure. Similarly, aldosterone recep-
tor antagonists (aldactone or eplerenone) are reserved for some
special indications such as primary aldosteronism, resistant hyperten-
sion, or hypertension associated with congestive heart failure.
A systematic review of randomized placebo-controlled studies of
the five main categories of blood pressure-lowering drugs, i.e.
angiotensin-converting enzyme (ACE) inhibitors, angiotensin II re-
ceptor blockers, diuretics, CCBs, and beta-blockers has actually
demonstrated that all five categories of drug produce similar reduc-
tions in blood pressure.4 The average reduction reaches 9.1 mmHg
systolic and 5.5 mmHg diastolic at the standard dose and
7.1 mmHg systolic and 4.4 mmHg diastolic at the half-standard
dose. However, the tolerability profile of these classes differs signifi-
cantly, diuretics, CCBs, and beta-blockers causing dose-dependent
side-effects, an observation that was not made with ACE inhibitors.4
Angiotensin II receptor blockers have the best tolerability profile of
all antihypertensive drug classes. The main advantage of these five
classes of drugs is that they act to lower blood pressure through dif-
ferent mechanisms. Thus, they can be combined effectively and their
antihypertensive efficacy is additive. The only exception is the
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combination of two blockers of the RAS which has been associated
with an increased risk of renal events and hyperkalaemia and is there-
fore not indicated.
Today, although the concept of first-line therapies tends to dis-
appear,3 most guidelines recommend to start therapy with a RAS
blocker or a CCB in most conditions as recommended, for
example, by the British guidelines5 and the most recent ESH-ESC
guidelines.3 However, the choice of the first-line therapy is often
determined by the presence or absence of comorbidities as illu-
strated in Figure 1. It is obvious from the most recent European
recommendations that RAS blockers are the preferred class to initi-
ate therapy in hypertensive patients with all comorbidities except
coronary heart disease.
The purpose of the present review is todiscuss some debated issues
concerning the first-line therapies of hypertension and to present the
ongoing developments of the pharmacology of hypertension.
Angiotensin-converting enzyme
inhibitors orangiotensin II receptor
blockers: a false debate?
Blockers of the RAS have been available for the management of es-
sential hypertension since the early 1980s with the development of
ACE inhibitors. Since then, overwhelming evidence has been built
up indicating that ACE inhibitors significantly lower blood pressure
and have a very favourable impact on patients’ morbidity and mortal-
ity not only in essential hypertension, but also in patients with heart
failure and patients with diabetic and non-diabetic nephropathies. In
the 1990s, angiotensin receptor blockers (ARBs) became available.6
These latter provided the opportunity to block the RAS at a different
level, i.e. at the AT1 receptor with the potential to induce a more
complete blockade of the system, all the effects of angiotensin II
being inhibited at the receptor level whatever the source of angioten-
sin II. Clinical studies rapidly demonstrated that ARBs are as effective
as ACE inhibitors in lowering blood pressure,7 but also in reducing
proteinuria and retarding the progression of renal diseases. Angio-
tensin II receptor blockers were also as effective as ACE inhibitors
in heart failure.8 9
With the accumulation of studies and trials using ACE inhibitors
and ARBs, several meta-analyses have been performed to compare
the clinical benefits of these two approaches to block the RAS
system. These meta-analyses generated some debate about the po-
tential superiority of ACE inhibitors over ARBs in reducing total
and cardiovascular mortality and on the impact of ARBs on the inci-
dence of myocardial infarction.8 –10 One of the meta-analysis includ-
ing more recent studies suggested that ARBs and ACE inhibitors
provide similar clinical benefits.9 However, in a more recent
meta-analysis conducted by van Vark et al. and including .150 000
patients, RAS blockade was associated with a significant reduction
in total and cardiovascular mortality over control treatments, but
the authors found a decrease in mortality only in patients receiving
an ACE inhibitor and not in those receiving an ARB, though the differ-
ence between ARBs and ACE inhibitors did not reach statistical
significance.10 From this meta-analysis, ACE inhibitors were pro-
moted as superior to ARBs with a question mark on the role of
ARBs in preventing coronary events. Even more recently, Savarese
et al.11 performed another meta-analysis comparing the two
classes of RAS blockers in high cardiovascular risk patients without
heart failure. In this analysis which included 26 randomized trials in
.100 000 patients, both ACE inhibitors and ARBs reduced the risk
of the composite endpoints of myocardial infarction, stroke, and car-
diovascular mortality. A reduction of the risk of all-cause death was
found with ACE inhibitors. The authors, therefore, concluded that
ARBs are a valuable alternative to ACE inhibitors in patients in
whom ACE inhibitors cannot be used.11 In this respect, the most im-
portant study to cite is undoubtedly the Ongoing Telmisartan Alone
and in combination with Ramipril Global Endpoint trial (ONTAR-
GET) which actually compared the ACE inhibitor ramipril to the
ARB telmisartan in high cardiovascular risk patients a large propor-
tion of them being hypertensive.12 As shown in Figure 2, there was
no significant difference between the ACE inhibitor and the ARB in
terms of total or cardiovascular mortality. There was also no differ-
ence when looking at myocardial infarction, hospitalization for
heart failure or stroke. Thus, the one and only large trial comparing
the two treatment options failed to identify any relevant difference
except for the incidence of side-effects. Indeed, the tolerability
profile of the ARB was superior to that of the ACE inhibitor with sig-
nificantly less cough and angioedema. Regarding this latter complica-
tion which in certain cases may be life threatening, a recent
meta-analysis confirm the data of ONTARGET showing that the
risk of developing an angioedema was two-fold increase in patients
receiving an ACE inhibitor when compared with those receiving an
ARB.12,13 The tolerability profile of drugs in an important determin-
ant of the discontinuation rate in treated hypertensive patients. Thus,
a recent Italian survey has demonstrated that the ARBs with a long
duration of action have the smallest discontinuation rate when com-
pared with short-acting ARBs or ACE inhibitors in general
(Figure 3).14
More recently, a third approach to the inhibition of the RAS has
become available, i.e. direct renin inhibition using aliskiren. This
new way of blocking the renin–angiotensin– aldosterone system
was very promising as it provided the unique opportunity to block
Figure 1 Compelling indications for antihypertensive drug
classes according to comorbidities (adapted from Mancia et al.1,3).
RAS blocker, blockers of the renin–angiotensin system; D, diure-
tics; CCB, calcium channel blockers.
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theRASat its initial step. In clinical studies, aliskirenwas found tobean
effective long-acting antihypertensive drug with a comparable effi-
cacy with ARBs and ACE inhibitors.15 Unfortunately, the mitigated
results of the large clinical trials in particular ALTITUDE16 showing
no real benefit on top of another blocker of the RAS in patients
with type 2 diabetes has considerably reduced the initial enthusiasm
and nowadays, although aliskiren is still available on some markets for
the treatment of hypertensionalone or in combination with adiuretic
or a CCB, its future is compromised as it is difficult to demonstrated
added benefits in comparison with ACE inhibitors or ARBs. Of note,
recent ESH-ESC guidelines do not recommend the use of aliskiren in
association with another blocker of the RAS.3
In summary, the ACE inhibitor vs. ARB debate is a false debate as
both groups of drugs are very effective and provide important clinical
benefits in hypertension. The improved tolerability profile of ARBs
give them a slight advantage, but this latter is often counterbalanced
by the lower cost of ACE inhibitors although nowadays both most
ACE inhibitors and some ARBs are available as generics.
Calcium channel blockers: what
about third generation
dihydropyridines?
Calcium channel blockers represent an heterogeneous group of
antihypertensive drugs that includes verapamil, diltiazem, and dihydro-
pyridines. Today, the long-acting second generation dihydropyridine
amlodipine has largely taken the lead in the prescription of CCBs as
this compound became generic. Moreover, the results of several
large clinical trials such as the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT),17 the Valsartan
Antihypertensive Long-Term Use Evaluation trial (VALUE),18 the
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT),19 or the
ACCOMPLISH trial (Avoiding Cardiovascular events through
Combination therapy in Patients Living with Systolic Hypertension)20
have emphasized the interest of prescribing this type of compound to
achieve blood pressure targets in hypertension. Thus, amlodipine is
now the most frequent CCB component of fixed-dose combinations
in association with a RAS blocker.
In clinical practice, the discontinuation rate of CCBs is rather high
and the long-term persistence of CCBs is lower that than observed
with RAS blockers.21 The main reason to discontinue CCBs is the ap-
pearance of peripheral oedema. In the VALUE trial in which amlodi-
pine was compared with valsartan, 14.9% of patients developed
peripheral oedema with the ARB, and 32.9% with amlodipine.18
Thus, one-third of patients suffered from this side-effect. It is
known that the association of a CCB with a RAS blocker reduces
the incidence of peripheral oedema because of the effects of RAS
blockade on pre-capillary pressure.22 Nevertheless, in ASCOT
which compared the association of perindopril and amlodipine to
the combination of a thiazide diuretic and the beta-blocker atenolol,
23% of patients complained of peripheral oedema, and 14% of joint
swelling in the perindopril/amlodipine group.19 This suggests that
even when combined with a RAS blocker, the incidence of peripheral
oedema remains high and may be a limiting factor for the long-term
persistence of treatment.
Is it possible to reduce the incidence of peripheral oedema using
new generations of CCBs? In recent years, several new CCBs of
the third generation such as lercanidipine, lacidipine, or manidipine
have become available on some markets. The main characteristic of
these CCBs is that they induce less peripheral oedema than classical
second generation CCBs. Thus, several studies have demonstrated a
reduced incidence of peripheral oedema with the use of these new
CCBs. Borghi et al. have shown that the occurrence of peripheral
oedema can be reduced by 50% in patients who developed
oedema with amlodipine and were switched to lercanidipine.23 Simi-
larly, in a large survey (COHORT study), peripheral oedema oc-
curred in 18% of patients treated with amlodipine but only in 7 and
4% of patients receiving, respectively, lercanidipine and lacidipine.24
In a large Swiss survey in which the patients’ therapy was either
Figure2 Effect of telmisartan and ramipril on cardiovascular end-
points in the ONTARGET trial (adapted from Yusuf et al.12).
Figure 3 Drug adherences to cardiovascular drugs in primary
prevention. Results of a meta-analysis (adapted from Naderi
et al.45).
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initiated with or switched to lercanidipine or lercanidipine was added
on top of other treatments, the incidence of ankle oedema was.4%
at 6 months.25 The use of these new third generation CCBs has been
shown to improve drug persistence in treated hypertensive patients
in comparison with other CCBs with persistence values close to
those of a RAS blocker.26
Taken together, these results suggest that third generation CCB
may help to reduce the incidence of peripheral oedema in hyperten-
sivepatients. Today, newfixed-dose combinations are on the market,
which combine a RAS blocker and a third generation CCB such as
enalapril/lercanidipine.27 These new associations have been shown
to be effective and well tolerated in the management of hypertensive
patients including those with diabetic nephropathy.28 Their major
limitation, however, is that these combinations have never been
investigated in controlled morbidity/mortality trials.
Diuretics: hydrochlorothiazide or
chlorthalidone?
Diuretics belong to the main classes of antihypertensive drugs and
their prescription remains high despite the development of new
therapeutic classes. Indeed, owing to the high-salt consumption of
salt in the population and to the well-recognized role of salt intake
in the development of essential hypertension, diuretics have an im-
portant role in the management of hypertensive patients. Today,
diuretics are infrequently prescribed as a single agent but more com-
monly in association with a RAS blocker. Several diuretics are avail-
able on the market for the treatment of hypertension including
hydrochlorothiazide (HCTZ), chlorthalidone, and indapamide. In
clinical practice, the prescription of HCTZ outnumbers those of all
diuretics essentially because it became the diuretic of reference in
all fixed-dose combinations.
Recently, several questions have been raised regarding the place
of HCTZ in the management of hypertension.29 Is HCTZ really the
most effective diuretic at the actual recommended doses? Is
HCTZ as effective as other diuretics in preventing cardiovascular
events such as stroke or myocardial infarction or death? Indeed,
analysis of studies tended to suggest that HCTZ is less effective
in lowering blood pressure than RAS blockers or CCBs and
thereby induce less cardiovascular protection than these latter.
Moreover, almost all large trials, such as ALLHAT,17 SHEP (Systol-
ic Hypertension in Elderly People)30 or the HYpertension in the
Very Elderly Trial (HYVET)31 demonstrating a cardiovascular
benefit of diuretics, have used either chlorthalidone or indapa-
mide but not HCTZ.
Thus, recently, several post hoc analysis were conducted to evalu-
ate the antihypertensive efficacy of HCTZ in clinical studies and to
compare HCTZ to other diuretics in particular to chlorthalidone.
In the study by Peterzan et al., a meta-analysis was performed to in-
vestigate the dose–response relationship of the various diuretics
used for the treatment of hypertension.32 The studies included in
the analysis involved4683patients in.53comparisonarms.Accord-
ing to this analysis, HCTZ, chlorthalidone, and bendroflumethiazide
had markedly different potencies with the lowest potency being
attributed to HCTZ. However, there was no evidence of a difference
in maximum reduction of systolic BP by high doses of different
thiazides. The difference in potency observed for blood pressure
between thiazide diuretics was also noticed for the changes in
serum potassium and uric acid levels. The authors concluded that
the difference in antihypertensive efficacy of the various thiazide
diuretics was essentially due to their potency. In another analysis,
Roush et al.33 have performed a systematic review of randomized
trials in which one arm was based on either HCTZ or chlorthalidone
followed by two types of network meta-analyses, a drug-adjusted
analysis and an office systolic blood pressure-adjusted analysis. Inter-
estingly, for a comparable decrease in blood pressure, the risk of
developing a cardiovascular event was found to be higher with
HCTZ than with chlorthalidone. Of note, when compared with
HCTZ, the number needed to treat with chlorthalidone to avoid
one cardiovasculareventwas 27. The resultsof this analysis therefore
suggest that chlorthalidone is superior to HCTZ in preventing car-
diovascular events.
Considering these recent analyses, new drug combinations are
being developed in which chlorthalidone rather than HCTZ is asso-
ciated with a RAS blocker. This is the case, for example, of the angio-
tensin II receptor blocker azilsartan medoxomil which will be
available in association with chlorthalidone.34,35 Bakris et al.34 actually
compared the antihypertensive efficacy of the association of
azilsartan + HCTZ to azilsartan + chlorthalidone. Looking at
changes in office as well as ambulatory blood pressure, the ARB-
chlorthalidone was systematically found to induce a greater fall in
blood pressure. In another clinical study, Cushman et al. investigated
the 12 week blood pressure changes induced by azilsartan/chlortha-
lidone 40/25 or 80/25 mg in comparison with olmesartan/HCTZ 40/
25 mg in hypertensive patients.35 All fixed-dose combinations
induced a marked and 24 h sustained blood pressure reduction but
the two doses of azilsartan/chlorthalidone appeared to be superior
to the olmesartan/HCTZ combination.
In summary, there is an increasing debate on which diuretic is the
most appropriate for the management of hypertensive patients. Al-
though HCTZ has been repeatedly shown to have an additive antihy-
pertensive effect when administered in association with a RAS
blocker, some people are questioning the choice of HCTZ in all
fixed-dose combinations and suggest that one might actually prefer
either chlorthalidone or indapamide for which there is even more
clinical evidence of benefits on cardiovascular endpoints. Indeed,
both chlorthalidone and indapamide have used favourably in large
clinical trials, particularly in elderly hypertensive patients.31 As
stated in the last ESH-ESC guidelines,3 today no specific recommen-
dation favouring one diuretic can be made based on the actual clinical
evidence.
What about beta-blockers?
The use of beta-blockers in the management of hypertensive patients
has been questioned in some guidelines and British scientists havedis-
regarded beta-blockers from their guidelines as first-line therapy
because of their lower ability to prevent stroke in the ASCOT
trial19 and their inability to lower central blood pressure. In the last
ESH-ESC hypertension guidelines3; however, beta-blockers remain
as a therapeutic option in particular for hypertensive patients with
cardiac diseases such as heart failure or coronary heart disease. It is
also emphasized that not all beta-blockers have the same properties
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and that newer beta-blockers such as nebivolol or carvedilol may not
share the same vascular and metabolic effects than atenolol or meto-
prolol.36,37 For example, both nebivolol and carvedilol have been
shown to lower central blood pressure in contrast to atenolol and
metoprolol. Nonetheless, it has to be mentioned that the newer
beta-blockers have been investigated essentially in patients with
heart failure and very few studies have been conducted with these
agents in hypertension.
What is the future of
antihypertensive therapy?
The pharmacological treatment of hypertension relies essentially on
the drug classes discussed above with their advantages and limita-
tions. Today, few new therapeutic drug strategies are being investi-
gated that might become available in the near future. Endothelin
antagonists have been studied in hypertension but because of their
side-effect profile (headaches and fluid retention), the focus has
now been directed towards the use of these agents in resistant hyper-
tension or hypertension of renal diseases.38 The combination of an
ACE inhibitor and an inhibitor of neutral endopeptidase was investi-
gated in the 1980s and resulted in good antihypertensive efficacy but
in increased incidence of angioedema. For this reason, the project
was abandoned. More recently, new attempts to combine an ARB
with a neprilysin inhibitor have been investigated and suggested
that inhibiting the RAS system and enhancing the vasodilatation
induced by atrial natriuretic peptides may be an effective way to
lower blood pressure.39,40 A new strategy is also expected in the
field of aldosterone blockade with the development of aldosterone
synthase inhibitors. Some phases II and III studies are ongoing with
these compounds.41 At last, the potential benefits of rho-kinase in-
hibition are being explored in arterial hypertension, but there is still
a long way to go until this class of compound arrives on the market.42
As long as these new treatment modalities are not on the market,
physicians will have to do the best they can to control blood pressure
with the tools available. In this respect, it is interesting to note the gap
between the results obtained in clinical trials where up to 80% of
patients can reach target blood pressures and the actual situation
of most countries which are at best 50% of patients with a con-
trolled blood pressure. Besides the issue of therapeutic inertia, one
of the most important problems of the management of hypertension
is the progressive discontinuation rate of treated patients who do not
stay on treatment.43 The low persistence in hypertension has been
clearly evidence in patients treated for hypertension in phase IV
studies.44 A recent meta-analysis has also shown that the long-term
adherence to cardiovascular drugs is particularly low in primary as
well as in the secondary prevention of cardiovascular diseases.45
Thus, all efforts should be done to improve drugpersistence in hyper-
tension in order to obtain the full-clinical benefits of the prescribed
treatments.
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